Aclaris Therapeutics, Inc. ACRS
We are a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. Our proprietary KINect drug discovery platform coupled with our integrated discovery approach to small and large molecules enables us to identify and advance product candidates designed to have superior target affinity, specificity and potency. We are seeking to identify and consummate transactions with third-party partners to further develop, obtain marketing approval for and/or commercialize our novel product candidates.
We are dedicated to developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. Our approach to achieving this goal includes the following key elements:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M | $6.5M | $4.2M | $6.2M | $1.7M | — |
| Cost of revenue | $2.1M | $2.8M | $3.4M | $4.0M | $4.7M | $5.1M | $4.1M | $4.3M | $1.2M | — |
| Gross profit | $5.7M | $15.9M | $27.8M | $25.7M | $2.0M | $1.3M | $172.0K | $3.2M | $476.0K | — |
| R&D | $52.6M | $33.6M | $98.4M | $77.8M | $43.8M | $29.3M | $64.2M | $60.8M | $35.8M | $33.5M |
| SG&A | $22.0M | $22.2M | $32.4M | $25.1M | $23.6M | $20.5M | $27.8M | $25.8M | $18.9M | $11.8M |
| Total operating expenses | $84.2M | $160.7M | $128.6M | $119.6M | $96.5M | $57.4M | $115.3M | $90.9M | $56.0M | $48.6M |
| Operating income | -$76.4M | -$141.9M | -$97.4M | -$89.9M | -$89.7M | -$50.9M | -$111.1M | -$84.8M | -$54.4M | -$48.6M |
| Pre-tax income | -$64.9M | -$132.1M | -$88.8M | -$86.9M | -$90.9M | -$51.3M | -$113.5M | -$82.1M | -$70.4M | -$48.1M |
| Income tax | — | — | $367.0K | — | — | $182.0K | — | — | $1.8M | — |
| Net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M | -$90.9M | -$51.0M | -$161.4M | -$132.7M | -$68.5M | -$48.1M |
| EPS, basic | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 | — | — | — |
| EPS, diluted | -0.53 | -1.71 | -1.27 | -1.33 | -1.60 | -1.20 | -3.90 | -4.03 | -2.44 | -2.25 |
| Shares, diluted (wtd. avg.) | $122.6M | $77.3M | $69.8M | $65.2M | $56.7M | $42.5M | $41.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.0M | $24.6M | $39.9M | $45.3M | $27.3M | $22.1M | $35.9M | $57.0M | $20.2M | $30.2M |
| Short-term investments | $70.8M | $89.0M | $79.2M | $172.3M | $164.1M | $32.1M | $39.1M | $111.0M | $173.7M | $107.1M |
| Receivables | — | $318.0K | $298.0K | $484.0K | $623.0K | $772.0K | $704.0K | $563.0K | $481.0K | — |
| Inventory | — | — | — | — | — | — | $0 | $791.0K | — | — |
| Total current assets | $96.3M | $126.0M | $128.9M | $231.6M | $205.0M | $57.5M | $83.8M | $179.5M | $200.2M | $138.6M |
| Property, plant and equipment | $761.0K | $1.0M | $1.6M | $1.1M | $1.3M | $1.7M | $2.5M | $2.3M | $2.2M | $481.0K |
| Goodwill | — | — | — | — | — | — | — | $18.5M | $18.5M | — |
| Other intangibles | — | — | $269.0K | $7.0M | $7.0M | $7.1M | $7.2M | $7.3M | $7.3M | — |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M | $70.8M | $98.3M | $275.6M | $243.5M | $176.1M |
| Accounts payable | $13.2M | $4.7M | $8.9M | $10.4M | $10.0M | $5.3M | $9.9M | $11.7M | $7.8M | $2.8M |
| Total current liabilities | $28.6M | $31.6M | $31.0M | $21.9M | $22.9M | $14.9M | $22.4M | $27.3M | $12.8M | $6.2M |
| Long-term debt | — | — | — | — | — | $10.7M | — | $29.9M | — | — |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57.0M | $53.9M | $33.1M | $28.4M | $60.4M | $18.2M | $6.6M |
| Retained earnings | -$967.8M | -$902.9M | -$770.8M | -$682.3M | -$595.4M | -$504.5M | -$453.5M | -$292.2M | -$159.4M | -$90.9M |
| Total equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M | $37.6M | $69.9M | $215.1M | $225.3M | $169.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$47.1M | -$20.1M | -$78.3M | -$67.6M | -$52.1M | -$38.6M | -$96.4M | -$100.8M | -$54.7M | -$34.6M |
| Depreciation and amortisation | $454.0K | $807.0K | $863.0K | $797.0K | $923.0K | $1.3M | $6.4M | $1.9M | $402.0K | $120.0K |
| Stock-based compensation | $12.4M | $10.9M | $20.5M | $15.0M | $14.1M | $11.2M | $16.2M | $20.1M | $14.4M | $6.1M |
| Capital expenditure | $111.0K | $121.0K | $1.3M | $605.0K | $308.0K | $453.0K | $1.6M | $1.4M | $1.2M | $232.0K |
| Investing cash flow | $48.4M | -$69.8M | $46.2M | $12.6M | -$167.6M | $6.4M | $105.7M | $9.4M | -$55.7M | -$61.9M |
| Financing cash flow | -$5.9M | $74.5M | $26.7M | $72.9M | $225.1M | $18.4M | -$30.3M | $128.3M | $100.4M | $116.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-047262.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |